Skip to main content

Plan For Narrowing A Field Of Zantac Lawsuits

Plan For Narrowing A Field Of Zantac Lawsuits

Plan For Narrowing A Field Of Zantac Lawsuits

Introduction

A joint plan to narrow more than 130,000 potential personal injury claimants accusing alleged links between the heartburn drug Zantac and various cancers has been presented by the parties of the Zantac MDL.

Florida-based U.S. District Judge Robin L. Rosenberg is overseeing the Zantac MDLs and informed that he will have a conference with attorneys for the consumers and various drugmakers to look into the "gray" areas of the MDL.

Earlier, Judge Rosenberg trimmed major  claims against generic-drug makers and retailers, but still, pharmaceutical brands were left out facing accusations of false advertising, failure to warn and other claims associated with the alleged discovery of the cancer-causing chemical nitrosodimethylamine, or NDMA, in the medication. The companies included including Sanofi, Pfizer Inc., Boehringer Ingelheim Pharmaceuticals Inc. and GlaxoSmithKline LLC.

The parties involved in the bellwether pool of the MDL have agreed to limit the plaintiffs residing in Florida itself. As per the stated agreement, 75% of the Florida plaintiffs will be bound to MDL court's orders and certify that they will file their complaints within the MDL. The first trial is slated for July 17, 2023, whereas November 15 is the deadline for getting the plaintiffs registered to the agreement.

The plan even outlines the limit of duration which plaintiffs need to abide by to provide discovery, including signed medical authorizations and a list of certain medical providers, with stipulations for curing deficiencies. These cases would be resolved by the court.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

NC to Get $150M to Boost Opioid Treatment, Recovery

Categories: Opioids

North Carolina will receive an additional $150 million from Purdue Pharma and the Sackler family as part of a national $7.4 billion settlement related to the opioid

SRI Gets FDA OK for High-Dose Naloxone Trial

Categories: Opioids

SRI has received authorization from the U.S. Food and Drug Administration (FDA) to begin Phase 1 clinical trials of a new, high-dose injectable naloxone formulation.

The approval was granted under an Investigational New Drug (IND)…

Spokane County to Get $5M in New Opioid Settlement

Categories: Opioids

Jurisdictions within Spokane County are set to receive nearly $4.7 million as part of a sweeping $7.4 billion nationwide settlement with Purdue Pharma and its owners, the Sackler family.

The agreement addresses the company’s role in fueling…

✍️ FREE—3000 Pages Medical Record Review Trial!                
No Contract. No Risk—Fully Customized, Free!

Only 10 Firms Accepted—Offer Ends June 30!